Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206079 | 0.87 | OPRM1 (0.54) | EPHX2OPRM1OPRL1EPHX1 | |
| SCHEMBL209001 | 0.87 | OPRM1 (0.43) | EPHX2ALDH1A1OPRM1OPRL1KMT2A | |
| SCHEMBL4072325 | 0.85 | OPRM1 (0.52) | EPHX2OPRM1OPRL1EPHX1 | |
| SCHEMBL206731 | 0.84 | HDAC3 (0.51) | EPHX2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2985381 | 0.81 | OPRM1 (0.48) | EPHX2HPGDOPRM1OPRL1CYP3A4 | |
| SCHEMBL207196 | 0.79 | OPRM1 (0.46) | EPHX2ALDH1A1OPRM1OPRL1ALOX15 | |
| Phenethylamine SCHEMBL206732 | 0.79 | EPHX2 (0.50) | EPHX2OPRM1OPRL1EPHX1 | |
| SCHEMBL2987110 | 0.79 | MEN1 (0.51) | EPHX2OPRM1OPRL1MEN1KMT2A | |
| SCHEMBL4049689 | 0.78 | KMT2A (0.53) | EPHX2HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL206620 | 0.78 | EPHX2 (0.46) | EPHX2KDM4EALDH1A1HPGDEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088763-B2 | e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases | GRUENENTHAL GMBH (DE) | 2012-01-03 | — | — | US | claimed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | claimed |
| US-8088763-B2 | e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases | GRUENENTHAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112007-A1 | Cyclohexyl-1, 4-diamine compounds | PKD1, DDC, DPYD | GAA 20/4885EPHX2 1203/4885KDM4E 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.